shutterstock_2075328976_jhvephoto

JHVEphoto / Shutterstock.com

7 December 2021GenericsAlex Baldwin

Galderma sues Lupin over Oracea generic

Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea (doxycycline) prior to the expiration of key patents.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Lupin and Sun settle Bromsite patent suit after ruling

10 February 2022 Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

Fed Circuit hands win to Galderma in Teva suit

30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Galderma fends off Dr Reddy IPR claims

17 February 2016 Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

More on this story

Lupin and Sun settle Bromsite patent suit after ruling

10 February 2022 Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

Fed Circuit hands win to Galderma in Teva suit

30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Galderma fends off Dr Reddy IPR claims

17 February 2016 Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

More on this story

Lupin and Sun settle Bromsite patent suit after ruling

10 February 2022 Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

Fed Circuit hands win to Galderma in Teva suit

30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Galderma fends off Dr Reddy IPR claims

17 February 2016 Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB